AR035317A1 - Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos - Google Patents
Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentosInfo
- Publication number
- AR035317A1 AR035317A1 ARP000102428A ARP000102428A AR035317A1 AR 035317 A1 AR035317 A1 AR 035317A1 AR P000102428 A ARP000102428 A AR P000102428A AR P000102428 A ARP000102428 A AR P000102428A AR 035317 A1 AR035317 A1 AR 035317A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- radicals
- alkyl
- maximum
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 -CH2-heterocyclic Chemical group 0.000 abstract 15
- 150000003254 radicals Chemical class 0.000 abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000005840 aryl radicals Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000009223 neuronal apoptosis Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9906456A FR2793794B1 (fr) | 1999-05-21 | 1999-05-21 | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035317A1 true AR035317A1 (es) | 2004-05-12 |
Family
ID=9545846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102428A AR035317A1 (es) | 1999-05-21 | 2000-05-19 | Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos |
Country Status (33)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413974B1 (en) * | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| US6969720B2 (en) | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
| EP1377579B1 (en) * | 2000-10-31 | 2009-03-25 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| US6861524B2 (en) * | 2000-10-31 | 2005-03-01 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
| US6812232B2 (en) | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| CA2463563A1 (en) * | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| AU2003301407B2 (en) * | 2002-10-15 | 2010-04-22 | Irm Llc | Compositions and methods for inducing osteogenesis |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| WO2005047524A2 (en) | 2003-11-10 | 2005-05-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
| AU2005231440B9 (en) * | 2004-04-02 | 2012-02-23 | Dogwood Pharmaceuticals, Inc. | Selective antagonists of A2A adenosine receptors |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| WO2012142029A2 (en) | 2011-04-10 | 2012-10-18 | Florida A&M University | Serms for the treatment of estrogen receptor-mediated disorders |
| WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP4086257A1 (en) * | 2016-09-30 | 2022-11-09 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
| CZ308029B6 (cs) | 2017-03-20 | 2019-11-06 | Univerzita PalackĂ©ho v Olomouci | 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky |
| AR131380A1 (es) | 2022-12-16 | 2025-03-12 | Astrazeneca Ab | Purinas 2,6,9-trisustituidas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4008858A1 (de) * | 1990-03-20 | 1991-09-26 | Hoechst Ag | Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel |
| EP0841810B1 (en) * | 1991-12-05 | 2000-06-21 | Texas Instruments Incorporated | Method to improve a video signal |
| CA2084222C (en) * | 1991-12-06 | 2004-04-06 | David R. Borcherding | Novel trans cyclopentanyl purine analogs useful as immunosuppressants |
| CN1066147C (zh) * | 1995-11-01 | 2001-05-23 | 诺瓦提斯公司 | 嘌呤衍生物及其制备方法 |
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| WO1998016528A1 (en) * | 1996-10-11 | 1998-04-23 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
| WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| US6413974B1 (en) * | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
-
1999
- 1999-05-21 FR FR9906456A patent/FR2793794B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-09 TW TW089108817A patent/TWI284130B/zh not_active IP Right Cessation
- 2000-05-18 PL PL00352293A patent/PL352293A1/xx not_active Application Discontinuation
- 2000-05-18 DZ DZ003166A patent/DZ3166A1/xx active
- 2000-05-18 JP JP2000619799A patent/JP2003500407A/ja not_active Abandoned
- 2000-05-18 AT AT00929625T patent/ATE370951T1/de not_active IP Right Cessation
- 2000-05-18 NZ NZ515556A patent/NZ515556A/en unknown
- 2000-05-18 US US09/979,389 patent/US7122669B1/en not_active Expired - Fee Related
- 2000-05-18 DE DE60036102T patent/DE60036102T2/de not_active Expired - Fee Related
- 2000-05-18 TR TR2001/03349T patent/TR200103349T2/xx unknown
- 2000-05-18 PT PT00929625T patent/PT1183256E/pt unknown
- 2000-05-18 UA UA2001128864A patent/UA68441C2/uk unknown
- 2000-05-18 IL IL14644100A patent/IL146441A0/xx unknown
- 2000-05-18 HU HU0201649A patent/HUP0201649A3/hu unknown
- 2000-05-18 ES ES00929625T patent/ES2290033T3/es not_active Expired - Lifetime
- 2000-05-18 SK SK1672-2001A patent/SK16722001A3/sk unknown
- 2000-05-18 CA CA002374714A patent/CA2374714A1/fr not_active Abandoned
- 2000-05-18 BR BR0011282-8A patent/BR0011282A/pt not_active Application Discontinuation
- 2000-05-18 CN CNB008106509A patent/CN1298719C/zh not_active Expired - Fee Related
- 2000-05-18 AU AU47645/00A patent/AU4764500A/en not_active Abandoned
- 2000-05-18 CZ CZ20014163A patent/CZ20014163A3/cs unknown
- 2000-05-18 EA EA200101224A patent/EA005072B1/ru not_active IP Right Cessation
- 2000-05-18 AP APAP/P/2001/002355A patent/AP1477A/en active
- 2000-05-18 YU YU86601A patent/YU86601A/sh unknown
- 2000-05-18 MX MXPA01011834A patent/MXPA01011834A/es active IP Right Grant
- 2000-05-18 DK DK00929625T patent/DK1183256T3/da active
- 2000-05-18 WO PCT/FR2000/001335 patent/WO2000071543A1/fr not_active Ceased
- 2000-05-18 EP EP00929625A patent/EP1183256B1/fr not_active Expired - Lifetime
- 2000-05-18 KR KR1020017014800A patent/KR100707895B1/ko not_active Expired - Fee Related
- 2000-05-19 AR ARP000102428A patent/AR035317A1/es not_active Application Discontinuation
-
2001
- 2001-11-15 MA MA26410A patent/MA26791A1/fr unknown
- 2001-11-20 NO NO20015659A patent/NO20015659L/no not_active Application Discontinuation
- 2001-11-21 ZA ZA200109602A patent/ZA200109602B/xx unknown
-
2004
- 2004-12-07 US US11/006,013 patent/US7208598B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
| ES2067508T3 (es) | Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso. | |
| ES2150577T3 (es) | Aminoeteres aromaticos como agentes para aliviar el dolor. | |
| EA199800943A1 (ru) | Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| ES2097659T3 (es) | Derivados antimitoticos de los alcaloides binarios del catharanthus roseus. | |
| LU91196I2 (fr) | Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO). | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| AR036663A1 (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos | |
| FI904327A0 (fi) | N-substituerad-4-pyrimidinaminer och -pyrimidindiaminer, foerfarande foer deras framstaellning och deras anvaendning som laekemedel. | |
| EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| GT200000183A (es) | Aminoacidos biciclicos como agentes farmaceuticos. | |
| AR033356A1 (es) | Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| MX9303441A (es) | Procedimiento para la preparacion de acido clavulanico. | |
| AR041271A1 (es) | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
| AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
| AR024944A1 (es) | Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion | |
| MX9503529A (es) | Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen. | |
| UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
| AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
| EA200400475A1 (ru) | Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |